行情

LXRX

LXRX

莱斯康制药
NASDAQ

实时行情|Nasdaq Last Sale

1.922
-0.008
-0.43%
交易中 12:38 08/11 EDT
开盘
1.940
昨收
1.930
最高
1.942
最低
1.885
成交量
51.34万
成交额
--
52周最高
5.33
52周最低
1.220
市值
2.06亿
市盈率(TTM)
10.29
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

中性

免责声明：分析师观点仅供投资者决策参考，不构成任何买卖投资建议。

目标价格预测

分析师预测LXRX价格均价为2.700，最高价位3.000，最低价为2.100。

EPS

LXRX 新闻

更多
5 Value Stocks To Watch In The Healthcare Sector
Benzinga · 23小时前
Lexicon Pharmaceuticals Intends To Implement Reduction In Force, Which Will Reduce Workforce By About 50% Related To Tersera Therapeutics Agreement
-Reuters
Reuters · 08/04 10:18
Lexicon Pharmaceuticals shares are trading higher. The Company last week announced it will sell Xermelo to GTCR and TerSera Therapeutics for an upfront purchase price of approximately $159 million along with potential milestone payments. NOTE: GTCR issued a press release today detailing the acquisition.
Benzinga · 08/03 13:35
Lexicon Pharma sells rights to Xermelo for $159M for new use
Seeking Alpha - Article · 08/03 12:25
GTCR And TerSera Therapeutics Issue Press Release Detailing Definitive Agreement To Acquire Xermelo From Lexicon Pharmaceuticals For $159M Plus Potential Milestones. BZ NOTE: Lexicon Announced Sale Of Xermelo Last Week
CHICAGO, Aug. 3, 2020 /PRNewswire/ -- GTCR, a leading private equity firm, announced today that its TerSera Therapeutics LLC ("TerSera") portfolio company has entered into a definitive agreement toCHICAGO, Aug.
Benzinga · 08/03 11:32
GTCR and TerSera Therapeutics Announce Acquisition of Xermelo
GTCR, a leading private equity firm, announced today that its TerSera Therapeutics LLC ("TerSera") portfolio company has entered into a definitive agreement to acquire the product Xermelo® (telotristat ethyl) from Lexicon Pharmaceuticals, Inc. ("Lexicon"; NASD
PR Newswire · 08/03 11:25
TAOP, KODK among premarket losers
Seeking Alpha · 07/31 12:16
Lexicon Pharmaceuticals Returning To Its Pre-Revenue Biotech Days
Seeking Alpha · 07/31 04:00

所属板块

生物技术和医学研究
-0.76%
制药与医学研究
0.00%

热门股票

代码
价格
涨跌幅

LXRX 简况

Lexicon Pharmaceuticals, Inc.（Lexicon）是一家生物制药公司。该公司专注于开发治疗人类疾病的药物。该公司正在开发两种候选药物：telotristat etiprate（LX1032）和sotagliflozin（LX4211）。telotristat etiprate是一种用于治疗类癌综合征的口服小分子候选药物。LX1032抑制色氨酸羟化酶（TPH），是该公司正在开发的用于治疗类癌综合征的口服小分子化合物药物。Sotagliflozin（LX4211）是正在开发的用于治疗1型和2型糖尿病的口服小分子化合物药物。LX2761是用于治疗糖尿病的口服小分子化合物药物。LX9211是用于治疗神经性疼痛的口服小分子化合物药物。该公司还开发其他药物，包括LX1033、LX2931和LX7101。
展开

微牛提供Lexicon Pharmaceuticals, Inc.(NASDAQ-LXRX)的股票价格，实时市场报价，专业分析师评级，深度图表和免费的LXRX股票新闻，以帮助您做出投资决策。

模拟交易：模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易LXRX股票基本功能。